Healthcare New Highs: China Cord Blood Corporation (NYSE:CO), Corcept Therapeutics (NASDAQ:CORT), Nordion (NYSE:NDZ), Vision-Sciences (NASDAQ:VSCI)

Stocks Almost Family and Chemed hold a Zacks Rank #1(Strong Buy) and China Cord Blood Corporation (NYSE:CO) holds a Zacks Rank #2 (Buy). With favorable Zacks Ranks, these stocks may be better selections at this time. China Cord Blood Corporation (NYSE:CO) stock performance was 3.26% in last session and finished the day at $4.44. Traded volume was 777.52K shares in the last session and the … Continue reading Healthcare New Highs: China Cord Blood Corporation (NYSE:CO), Corcept Therapeutics (NASDAQ:CORT), Nordion (NYSE:NDZ), Vision-Sciences (NASDAQ:VSCI)

Investors Watch List: Salesforce.com (NYSE:CRM), Corcept Therapeutics Incorporated (NASDAQ:CORT), Rally Software Development Corp. (NYSE:RALY), Vodafone (NASDAQ:VOD), First Commonwealth Financial (NYSE:FCF)

On 21 AUG Salesforce.com, Inc (NYSE:CRM) last announced its earnings results on Thursday. The company reported $0.13 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.12 by $0.01. The company had revenue of $1.32 billion for the quarter, compared to the consensus estimate of $1.29 billion. During the same quarter in the previous year, the company posted $0.09 earnings per share. … Continue reading Investors Watch List: Salesforce.com (NYSE:CRM), Corcept Therapeutics Incorporated (NASDAQ:CORT), Rally Software Development Corp. (NYSE:RALY), Vodafone (NASDAQ:VOD), First Commonwealth Financial (NYSE:FCF)

La Jolla Pharmaceutical Company (NASDAQ:LJPC) (the “Company” or “La Jolla”) a leader in the development of therapeutics targeting significant unmet life-threatening diseases today announced that George Tidmarsh M.D. Ph.D. President and Chief Executive Officer will provide a corporate overview at the 2014 Wedbush Securities Life Sciences Conference taking place August 12-13 in New York City. La Jolla Pharmaceutical Co. (NASDAQ:LJPC) belongs to Healthcare sector. Its … Continue reading Worth Watching Stocks : La Jolla Pharmaceutical (NASDAQ:LJPC), Corcept (NASDAQ:CORT), Grupo Aeroportuario (NASDAQ:OMAB), Facebook (NASDAQ:FB), Elephant Talk Communications (NYSEMKT:ETAK)

Aegis started coverage on shares of Recro Pharma Inc. (NASDAQ:REPH) in a research note issued on Thursday, TheFlyOnTheWall.com reports. The firm set a “buy” rating and a $40.00 price target on the stock. Aegis’ price objective suggests a potential upside of 412.16% from the company’s current price. Recro Pharma Inc (NASDAQ:REPH) stock performance was -7.30% in last session and finished the day at $7.24. Traded … Continue reading Biotech Decliners: Recro Pharma Inc (NASDAQ:REPH), Ignyta Inc (NASDAQ:RXDX), Alder Biopharmaceuticals Inc (NASDAQ:ALDR), Corcept Therapeutics Incorporated (NASDAQ:CORT)

Corcept Therapeutics Inc (NASDAQ:CORT) Director G Leonard Baker, Jr. bought 103,386 shares of the stock in a transaction that occurred on Wednesday, June 11th. The stock was purchased at an average cost of $2.32 per share, for a total transaction of $239,855.52. Following the completion of the transaction, the director now directly owns 578,389 shares of the company’s stock, valued at approximately $1,341,862. Corcept Therapeutics … Continue reading Healthcare losers: Corcept Therapeutics Incorporated (NASDAQ:CORT), OncoGenex Pharmaceuticals (NASDAQ:OGXI), Anika Therapeutics (NASDAQ:ANIK), Oncomed Pharmaceuticals (NASDAQ:OMED), Cesca Therapeutics (NASDAQ:KOOL)

Seattle Genetics, Inc (NASDAQ:SGEN) Director Felix Baker purchased 281,963 shares of Seattle Genetics stock in a transaction dated Wednesday, June 4th. The stock was purchased at an average price of $34.86 per share, for a total transaction of $9,829,230.18. Following the transaction, the director now directly owns 76,997 shares of the company’s stock, valued at approximately $2,684,115. Seattle Genetics, Inc. (NASDAQ:SGEN) stock performance was -0.05% … Continue reading Biotech Insider Buying: Seattle Genetics (NASDAQ:SGEN), Corcept Therapeutics Incorporated (NASDAQ:CORT), Cytori Therapeutics (NASDAQ:CYTX), Oramed Pharmaceuticals (NASDAQ:ORMP), Biota Pharmaceuticals (NASDAQ:BOTA)